Measuring ribavirin concentrations during the earliest stages of antiviral therapy for hepatitis C: potential relevance for treatment outcome.

MLA

van Vlerken, Lotte G., et al. “Measuring Ribavirin Concentrations during the Earliest Stages of Antiviral Therapy for Hepatitis C: Potential Relevance for Treatment Outcome.” Therapeutic Drug Monitoring, vol. 35, no. 4, Aug. 2013, pp. 546–51. EBSCOhost, https://doi.org/10.1097/FTD.0b013e31828a9fbf.

APA

van Vlerken, L. G., de Kanter, C. T. M. M., Boland, G. J., van Loon, A. M., van Soest, H., Koek, G. H., Drenth, J. P. H., Siersema, P. D., van Erpecum, K. J., & Burger, D. M. (2013). Measuring ribavirin concentrations during the earliest stages of antiviral therapy for hepatitis C: potential relevance for treatment outcome. Therapeutic Drug Monitoring, 35(4), 546–551. https://doi.org/10.1097/FTD.0b013e31828a9fbf

Chicago

van Vlerken, Lotte G, Clara T M M de Kanter, Greet J Boland, Anton M van Loon, Hanneke van Soest, Ger H Koek, Joost P H Drenth, Peter D Siersema, Karel J van Erpecum, and David M Burger. 2013. “Measuring Ribavirin Concentrations during the Earliest Stages of Antiviral Therapy for Hepatitis C: Potential Relevance for Treatment Outcome.” Therapeutic Drug Monitoring 35 (4): 546–51. doi:10.1097/FTD.0b013e31828a9fbf.